After a delayed last patient in (LPI) date, IQVIA Biotech reviewed the tactics and helped devise and execute a campaign that helped sites complete enrollment for Phase I and Phase IIa acne vulgaris studies in Canada.
You may also be interested in
You are about to exit for another IQVIA country or region specific website
Please be aware that the website you have requested is intended for the residents of particular country or region, as noted on that site.
Get in touch today to discover the right solutions for you.